Published on Wed Sep 22 2021

mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?

Wijtvliet, V. P. W. M., Arien, K. K., Abrams, S., Couttenye, M. M., Mestrez, F., Marien, J., De Winter, B. Y., Van Damme, P., Pipeleers, L., Wissing, K. M., Abramowicz, D., Ledeganck, K.

Vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean antibody titers compared to BNT162b2 (Pfizer)

8
35
140
Abstract

In this study of the humoral immune response after the first dose of SARS-CoV-2 mRNA vaccine, low seroconversion rates were noted in both kidney transplant recipients and dialysis patients. However, vaccination with the mRNA-1273 vaccine (Moderna) resulted in both higher seroconversion rates and mean antibody titers compared to BNT162b2 (Pfizer).